The Bedrobinol cannabinoid composition is made up of 13.5% THC and lower than 1% CBD. It also includes small amounts of other minor cannabinoids. Bedrondiol terpene profile is dominated by 10mg (per gram) of myrcene, which has shown in preliminary studies to have antibiotic, antimutagenic, analgesic and anti-inflammatory effects. It also includes smaller amounts of a variety of other terpenes including alpha-2-pinene (2mg), BCP (1mg) and beta-2-pinene (0.8mg) per gram. Early research is supporting the theory of the ‘entourage effect’. This phenomenon occurs when a patient uses a whole plant product like Bedrobinol, the cannabinoids and terpenes work together and interact with the endocannabinoid system synergistically to improve the overall effects for patients.
Bedrocan avoids milling and blending strains with different cannabinoid content. While milling and blending can afford accuracy in THC and CBD content, it fails to produce consistency in plants other cannabinoids and terpene profile. Bedrocan’s method provides unrivalled accuracy in cannabinoid and terpene profile, meaning the final product meets the same high standards expected for traditional prescription medicines.
Patients can either administer the product through inhalation or orally in food and drink. It is recommended that users start on a low dosage for a week and assess the results. Over time, the patient can slowly increase the dose until they find their optimal level. If the product is used orally, the patient can expect an onset time between 1-2 hours and a duration of action of 6-10 hours. Patients can expect a much faster onset time of around 5-10 minutes with a shorter duration of action of 2-4 hours when consuming the product via inhalation.
It is important to mention that this is a rough guideline. Onset and duration times can vary depending on a range of factors such as the strength of cannabinoids, or natural bodily variations in different people such as metabolism, weight or body fat percentage.
Bedrocan understands the importance of lab testing and follows a strict process to ensure each batch of medical cannabis is up to standard. As soon as the plant is harvested, the product is sent to a specialised, third-party laboratory (LAB OFICHEM) for extensive toxicology testing to check for harmful substances such as pesticides, heavy metals and other pathogens. The product is also tested for its cannabinoid and terpene profiles to ensure that Bedrocan products always have the correct levels of each active ingredient and the same composition. Bedrocan does not release batches of medical cannabis until they have been fully approved by the independent laboratory. This endeavour for accuracy provides patients with the confidence they need to start using medical cannabis.